Search

Displaying results 4241 - 4250 of 9132 in total
  1. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

  2. Drug

    Homatropine methylbromide

    go.drugbank.com/drugs/DB00725
    Approved

    Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.

  3. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  4. Drug

    Clotiazepam

    go.drugbank.com/drugs/DB01559
    ApprovedIllicit

    Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.

  5. Drug

    Lonoctocog alfa

    go.drugbank.com/drugs/DB13998
    ApprovedInvestigational

  6. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  7. Drug

    Fusafungine

    go.drugbank.com/drugs/DB08965
    ApprovedWithdrawn

    Fusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.

  8. Drug

    Tyrosinase

    go.drugbank.com/drugs/DB16626
    Investigational

    as melanogenesis). … [A231829, A231834, A231839] Within mammals, tyrosinase is found specifically in melanocytes in a glycosylated form and plays a critical role in regulating the process of melanin biosynthesis (also known

    Synonyms: Tumor rejection antigen AB
  9. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  10. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Pegvaliase-pqpz, or PEGylated pegvaliase, is used as a novel enzyme substitution therapy and is marketed as Palynziq for subcutaneous injection. … The presence of a PEG moiety in pegvaliase-pqpz allows a reduced immune response and improved pharmacodynamic stability [A33284].